Genxone S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-08-08
Share capital
3,304,820.00 PLN
Activity description

Genxone is a laboratory specializing in next generation sequencing (NGS) and molecular diagnostics, utilizing nanopore sequencing technology developed by Oxford Nanopore Technologies. It offers a range of sequencing services, including metagenomic sequencing, 16s and/or ITS gene sequencing, and whole genome sequencing. Additionally, Genxone provides custom-designed analysis and bioinformatics services.

Registered address
ul. Kobaltowa 6, 62-002 Złotniki, Poland
Website
Email
Electronic delivery address
AE:PL-56197-43924-RTSTC-28

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0

Filing timeliness

Financial statements were filed on time, on average 32 days early. All were audited by a statutory auditor.

  • 202526/06/2026
  • 202425/06/2025
  • 202326/06/2024
  • 202222/06/2023
  • 202117/06/2022
  • 202027/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 4.58
-0.02 (-0.43%)
4.584.594.604.58Nov 13Nov 16
Open
PLN 4.58
High
PLN 4.58
Low
PLN 4.58
Volume
3
Avg. vol.
706
Market cap
PLN 15.14M
P/E ratio
–
EPS
-PLN 0.43
Shares outstanding
3.3M
52-week
PLN 4.50 – 5.38
Dividend yield
21.83%
Dividend
PLN 1.00
Ex dividend date
Jun 16, 2022
Exchange
NewConnect

Quarterly results

PeriodRevenueEBITNet profit
Q3 2026USD 176.39kUSD -129.93kUSD -125.34k
Q2 2026USD 153.16kUSD -94.27kUSD -88.87k
Q1 2026USD 132.63kUSD -145.60kUSD -139.65k
Q4 2025USD 230.29kUSD -57.76kUSD -49.22k

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 19%
City · Złotniki46 / 105
Top 44%
Voivodeship · Wielkopolskie12,009 / 30,850
Top 39%
Country · Poland109,287 / 297,069
Top 37%

Results vs industry

Revenue
This companyUSD 665.36kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -662.89kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 1.19mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 2.25mMedianUSD 134.71kAverageUSD 3.04m

Websites

  • nanobiome.plNanobiome – polskie badanie mikrobioty jelitowej
    WooCommerce 8.1WordPress 6.3ElementorGoogle AdsGoogle AnalyticsGoogle Tag Manager

Public procurement

7 tenders recorded as contractor, with a total value of $384,416.

SubjectAmount
Comprehensive microbiome next-generation sequencing service
$66,647
Successive supply of chemical reagents and microbiological materials under a framework agreement for Wojewódzka Stacja Sanitarno-Epidemiologiczna w Rzeszowie
$36,029
Purchase of a system for analyzing bacterial antibiotic resistance genes, including the lease of a nanopore next-generation sequencing device for UCK.
$59,959

Authorized Representatives

Agata Joanna Kozioł-Jaworska age 50 – Attorney-in-fact (sole)
Anna Strumnik age 40 – Vice President of the Management Board
Michał Kaszuba age 51 – President of the Management Board

Manner of representation

If one member of the management board has been appointed, that member is entitled to independently represent the company. If a multi-member management board has been appointed, the company shall be represented individually by each member of the management board.

Supervisory board

Piotr Bartosz Ciżkowicz age 47 – Supervisory Board Member
Mariusz Cezary Koitka age 61 – Supervisory Board Member
Dariusz Zowczak age 62 – Supervisory Board Member
Jakub Józef Swadźba age 60 – Supervisory Board Member
Janusz Kraśniak age 62 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2016-11-17.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 11,896

MSiG notices

6 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Jun 18, 2020Shareholders' meeting convened
Feb 26, 2020Shareholders' meeting convened
Dec 19, 2019Commercial Companies Code notice
Nov 12, 2019Commercial Companies Code notice
Nov 4, 2019Call to creditors

Public aid

9 public aid cases recorded, with a total value of $1,118,093.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$10,556
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$5,538
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$5,542

European Funds

ProjectEU co-financing
Development of an innovative test for diagnosing postoperative wounds using next-generation sequencing (NGS) technology.
$912K
Preparation of documentation to obtain external financing for GENXONE Sp. z o.o. through a share issue and their debut on the NewConnect market of GPW w Warszawie
$27,398

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Toxlab sp. z o.o.
Zakład Genetyki Sądowej sp. z o.o.
Polbiotech Laboratorium sp. z o.o.
Precisionlife Poland sp. z o.o.
Camino Science sp. z o.o.
Vaxican sp. z o.o.
Rivbio sp. z o.o.
Seqme S.R.O. Branch (foreign co.)
Nexbio sp. z o.o.
Intelliseq S.A.

Change history

DateEvent
2024-07-19Share capital increase
2023-07-27Share capital increase
2020-06-15Share capital increase
2019-09-17Share capital increase
2019-06-19Share capital increase

FAQ

Last updated: 2026-07-09